A Randomized, Placebo Controlled, Repeat Dose, Double Blind (Sponsor Unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs GSK 2330672 (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.